Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

39.34 -0.48 (-1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
For those who appreciate growth without the sticker shock, NASDAQ:TGTX is worth considering.
NASDAQ:TGTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:TGTX.
TG THERAPEUTICS INC (NASDAQ:TGTX) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Market Hits Record Highs On Big Fed Rate Cut; Apple, Intel, FedEx In Focus: Weekly Review
TheApple iPhone 16 went on sale amid mixed signals about demand. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
Via Benzinga
What's Going On With TG Therapeutics Stock Wednesday?
TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials. 
Via Benzinga
Why NASDAQ:TGTX is Poised for High Growth.
Exploring TG THERAPEUTICS INC (NASDAQ:TGTX)'s growth characteristics. 
Via Chartmill
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
NASDAQ:TGTX, a growth stock which is not overvalued. 
Via Chartmill
Decoding TG Therapeutics's Options Activity: What's the Big Picture?
Via Benzinga
IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
The company unveiled five-year test results for its multiple sclerosis drug, Briumvi. 
Via Investor's Business Daily
Despite its growth, NASDAQ:TGTX remains within the realm of affordability.
While growth is established for TG THERAPEUTICS INC (NASDAQ:TGTX), the stock's valuation remains reasonable. 
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
TG THERAPEUTICS INC (NASDAQ:TGTX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
What's Going On With ADMA Biologics Stock Monday?
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why the growth investor may take a look at NASDAQ:TGTX.
Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for growth investing? 
Via Chartmill
A Closer Look at TG Therapeutics's Options Market Dynamics
Via Benzinga
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
The company reported a surprise profit in the second quarter, vs. expectations for losses. 
Via Investor's Business Daily
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
NASDAQ:TGTX: a strong growth stock preparing for the next leg up?.
TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank. 
Via Chartmill
$1000 Invested In TG Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
TGTX Stock Earnings: TG Therapeutics Beats EPS, Beats Revenue for Q2 2024
TGTX stock results show that TG Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%
The company unexpectedly reported profit in the second quarter, handily beating views for a per-share loss. 
Via Investor's Business Daily
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
Looking for growth without the hefty price tag? Consider TG THERAPEUTICS INC (NASDAQ:TGTX). 
Via Chartmill
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Our first-ever twin bill. 
Via The Motley Fool
Nasdaq 100 Overbought? Here’s What History Says About The Current Rally
Find out the historical patterns traders can look for to anticipate the next move in the Nasdaq 100. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.